



20 **SUMMARY**

21 DOT1L, the only H3K79 methyltransferase in human cells and a homolog of the yeast Dot1,  
22 normally forms a complex with AF10, AF17 and ENL/AF9, is dysregulated in most of the cases  
23 of mixed lineage leukemia (MLL) and is believed to regulate transcriptional elongation without  
24 much evidence. Here we show that the depletion of DOT1L reduced the global occupancy  
25 without affecting the traveling ratio or the elongation rate of Pol II, suggesting it not a major  
26 elongation factor. An examination of general transcription factors (GTFs) binding revealed  
27 globally reduced TBP and TFIIA occupancies near promoters after DOT1L loss, pointing to a  
28 role in transcriptional initiation. Proteomic studies uncovered that DOT1L regulates  
29 transcriptional initiation likely by facilitating the recruitment of TFIID. Moreover, ENL, a DOT1L  
30 complex subunit with a known role in DOT1L recruitment, also regulates transcriptional  
31 initiation. Furthermore, DOT1L stimulates H2B monoubiquitination by limiting the recruitment of  
32 human SAGA complex, and the connection between Dot1/DOT1L and SAGA complex is  
33 conserved between yeast and human. These results advanced current understanding of roles  
34 of DOT1L complex in transcriptional regulation and MLL.

35

## 36 INTRODUCTION

37 Transcription is the first step of gene expression, cell type-specific transcription is  
38 fundamental to the development of multicellular organisms, and mutations of transcription  
39 factors (TFs) are found in more than 50% of all cancer cases <sup>1</sup>. Among the three eukaryotic  
40 RNA polymerases, i.e., Pol I, II and III, the regulation of Pol II transcription is the focus of  
41 research because of the large number of protein-coding genes with varying lengths and  
42 therefore the complexity of the underlying mechanisms. Transcription is divided into three  
43 stages, including initiation, elongation and termination. In the initiation of Pol II transcription, six  
44 general transcription factors (GTFs), i.e. TFIIA, B, D, E, F and H, form a preinitiation complex  
45 (PIC) with Pol II for the recognition of a transcriptional start site (TSS) and the creation and  
46 stabilization of a transcription bubble <sup>2</sup>. TFIID contains TBP and 13 TBP-associated factors  
47 (TAFs), and is critical for the recognition of promoters and the subsequent PIC assembly <sup>3</sup>.  
48 Interestingly, three of the TAFs (TAF9, 10 and 12) were also found to be parts of the Spt-Ada-  
49 Gcn5-acetyltransferase (SAGA) complex, which contains TBP loading, activator binding,  
50 acetyltransferase, and deubiquitinase modules <sup>4</sup>. In the yeast *Saccharomyces cerevisiae*, the  
51 TBP loading function and therefore a role in transcriptional initiation of the SAGA complex have  
52 been well-established <sup>5,6</sup>, although it is less clear why some of the promoters are TFIID  
53 dependent and others are SAGA dependent. In contrast, the SAGA complex was found to play  
54 a post initiation role in metazoans<sup>7</sup>. Nevertheless, compared with the molecular details of  
55 ordered PIC assembly, the regulation of PIC assembly by TFs and epigenetic regulators is less  
56 well understood.

57

58 In metazoans, elongation by Pol II includes two steps, i.e. promoter-proximal pause release  
59 of Pol II (PPPRP) and productive elongation, and PPPRP and initiation are recognized as  
60 critical checkpoints of transcriptional regulation <sup>8</sup>. The binding of NELF and DSIF to elongating  
61 Pol II 20 to 80 nt downstream of transcription start sites (TSSs) stabilizes its promoter-proximal

62 pause, and the release requires kinase activity of P-TEFb, a heterodimer of CDK9 and Cyclin  
63 T1, and the PAF1 complex (PAF1C)<sup>9,10</sup>. P-TEFb activity is elaborately regulate through  
64 incorporation into both the 7SK snRNP ribonucleoprotein complex, in which its kinase activity is  
65 constrained<sup>11</sup>, and the multiprotein super elongation complex (SEC), in which it is active. The  
66 SEC is composed of AFF1/AFF4, AF9/ENL and ELL1 in addition to P-TEFb<sup>12</sup>, and the subunits  
67 separated by a “slash” are homologous and mutually exclusive in the complex<sup>13</sup>. Among the  
68 SEC subunits, AFF1, AFF4, AF9, ENL, and ELL1 are common fusion partners of MLL1 in mixed  
69 lineage leukemias (MLLs), which account for over 70% of the infant leukemia cases and  
70 approximately 10% of the adult acute myeloid leukemia (AML) cases<sup>14</sup>. MLL1 is a member of  
71 the SET1/MLL family methyltransferases in human cells that affect chromatin structure and  
72 gene expression by methylation of H3K4 at key regulatory regions of the genome<sup>15</sup>.  
73 Particularly, promoter-associated H3K4 trimethylation (H3K4me3) has been shown to stimulate  
74 transcriptional initiation by serving as a binding site for the TAF3 subunit of TFIID<sup>16</sup>. MLL fusion  
75 proteins (MLL-FPs), arising from chromosomal translocations that lead to in-frame fusions of an  
76 *MLL1* 5' fragment to one of the more than sixty fusion partner genes, are sufficient to induce  
77 MLL, but usually require DOT1L for the activation of key target genes with incompletely  
78 understood mechanisms<sup>17</sup>.

79  
80 DOT1L, the only known H3K79 methyltransferase in human cells and a homolog of yeast  
81 Dot1, normally forms a complex with AF10, AF17 and AF9/ENL, two subunits shared with SEC  
82<sup>18,19</sup>. Within DOT1L complex, DOT1L is known to antagonize deacetylases SIRT1-mediated  
83 epigenetic silencing with incompletely understood mechanisms<sup>20</sup>, AF10 stimulates the  
84 conversion of H3K79 mono-methylation to di- and tri-methylation<sup>21</sup>, AF9 and ENL are capable  
85 of binding acetylated H3 and facilitating the recruitment of DOT1L<sup>22,23</sup>, and the function of AF17  
86 is less well understood. Moreover, AF10 and AF17 are also fusion partners of MLL1 in MLL<sup>14</sup>.  
87 However, mainly due to the association with Pol II<sup>24</sup>, sharing subunits with SEC and the

88 association of H3K79 di- and tri-methylation with the bodies of active genes, DOT1L is believed  
89 to regulate transcriptional elongation without sufficient evidence. Furthermore, the binding of  
90 Dot1/Dot1L to H2BK120 monoubiquitination (H2Bub1) is required for H3K79 methylation in both  
91 yeast and metazoans<sup>25</sup>, Dot1 is known to promote H2Bub1 by inhibiting the recruitment of  
92 SAGA complex in yeast<sup>26</sup>, and DOT-1.1 is known to suppress H2Bub1 in *C. elegans*<sup>27</sup>, but the  
93 effect and the underlying mechanisms in human cells are undetermined.

94

95 To understand roles of DOT1L complex in transcriptional regulation and MLL, we performed  
96 functional genomic studies in human cells, and discovered that DOT1L complex regulates  
97 transcriptional initiation likely by facilitating the recruitment of TFIID in both non-MLL and MLL  
98 cells and that DOT1L stimulates H2Bub1 by limiting the chromatin occupancy of human SAGA  
99 (hSAGA) complex.

100

## 101 **RESULTS**

### 102 ***DOT1L promotes the chromatin association of Pol II in human cells***

103 We chose human erythroleukemia cell lines, HEL and K562, for understating roles of  
104 DOT1L complex in transcriptional regulation in non-MLL cells because DOT1L is required for  
105 erythropoiesis<sup>28</sup> and it is easy to perform functional genomic studies with them. Promoter-  
106 associated Pol IIs and gene body-associated Pol IIs are highly phosphorylated on serine 5 (ser-  
107 5) and serine 2 (ser-2) of their C-terminal domain (CTD), respectively, and changes of CTD  
108 phosphorylation usually reflect transcriptional changes. To examine the effects of DOT1L loss  
109 on transcription, we knocked it down by a lentiviral shRNA in HEL cells, and analyzed the  
110 effects on two forms of CTD phosphorylated Pol II by Western blot (WB). DOT1L knockdown  
111 (KD) markedly reduced the level of CTD ser-2 phosphorylation of Pol II, indicating effects on  
112 transcriptional elongation (Figure S1A). However, chromatin occupancy changes of proteins do

113 not always follow their abundance changes. To examine the effects on Pol II chromatin  
114 occupancy, we performed ChIP-qPCR for total, ser-5 phosphorylated and ser-2 phosphorylated  
115 Pol II on *c-MYC* and *CTNNB1*. Consistent with the WB result, the chromatin occupancy of ser-2  
116 phosphorylated Pol II decreased after DOT1L KD (Figure S1B and C). Interestingly, the  
117 chromatin occupancies of total and ser-5 phosphorylated Pol II also decreased, suggesting that  
118 the effects of DOT1L loss on transcription is likely unlimited to elongation (Figure S1D and E).  
119 To determine if DOT1L regulates global Pol II occupancy in HEL cells, we performed ChIP-seq  
120 experiments for total and ser-2 phosphorylated Pol II. DOT1L KD reduced their global  
121 occupancies, pointing to a general role of DOT1L in promoting the chromatin association of Pol  
122 II in human cells (Figure 1A, B, and C). To assess the effect of DOT1L KD on transcriptome, we  
123 performed RNA-seq experiments. A subset of genes showed expression changes with 259  
124 downregulated and 266 upregulated after DOT1L KD (Figure S2A and B).

125  
126 To determine if DOT1L plays a general role in promoting the chromatin association of Pol II  
127 in non-MLL human cells, we performed total Pol II ChIP-seq experiments in control and DOT1L  
128 knockout (KO) K562 cells generated by the CRISPR-Cas9 technique (Figure 1D). The reduced  
129 global occupancy of Pol II after DOT1L KO supported a general role (Figure 1E and F). To  
130 determine if this is also the case in human MLL cells, we treated THP1 and MOLM-13 cells,  
131 respectively, with a potent DOT1L inhibitor, SGC0946. DOT1L inhibition reduced both the  
132 expression of and the occupancy of Pol II on common key target genes of DOT1L and MLL-AF9  
133 (Figure 1G, H, I, J, K, and L). Altogether, these data suggested that DOT1L is a general  
134 regulator for promoting the chromatin occupancy of Pol II in non-MLL and MLL human cells.

135

### 136 ***DOT1L may not play a major role in transcriptional elongation in human cells***

137 Transcriptional elongation is divided into PPRP and productive elongation. DOT1L is  
138 considered an elongation factor without sufficient evidence, and a recent study revealed that it

139 does not regulate PPPRP in mouse ES cells, but may affect downstream elongation<sup>29</sup>. To  
140 assess if it affects PPPRP in human cells, we calculated traveling ratio (TR)<sup>30</sup> of Pol II with total  
141 Pol II ChIP-seq data from HEL and K562 cells, respectively (Figure 2A). DOT1L KD or KO had  
142 little effect on the TR of Pol II (Figure 2B and C), consistent with results of the earlier study that  
143 DOT1L may not play a major role in PPPRP in human cells. To further validate this finding, we  
144 performed PRO-seq in control and DOT1L KD HEL cells to analyze the distribution of engaged  
145 Pol II and calculate TR. DOT1L KD reduced the chromatin occupancy but had almost no effect  
146 on the TR of engaged Pol II (Figure 2D, E and F), further supporting that DOT1L is unlikely to  
147 play a major role in the regulation of PPPRP. To determine if DOT1L affects the rate of  
148 productive elongation, we performed 4sUDRB-seq experiments, which is based on the  
149 reversible inhibition of transcriptional elongation with DRB and the labeling of newly transcribed  
150 RNA with uridine analog 4-thiouridine (4sU)<sup>31</sup>. We found that DOT1L KO minimally affected the  
151 productive elongation rate of Pol II (Figure 2G, H, I, J and K). Altogether, these data suggested  
152 that DOT1L may not play a major role in transcriptional elongation in human cells.

153

#### 154 ***DOT1L regulates transcriptional initiation in human cells***

155 Ordered binding of TBP, TFIIA and TFIIB to promoters precedes and facilitates Pol II  
156 recruitment in transcriptional initiation in eukaryotic cells. Reduced Pol II occupancy near TSSs  
157 in DOT1L depleted cells raised the possibility that DOT1L may regulate transcriptional initiation.  
158 To test if that is the case, we performed ChIP-seq experiments for TBP, TFIIA and TFIIB in  
159 control and DOT1L KO cells. DOT1L KO markedly reduced the global occupancies of TBP and  
160 TFIIA and the occupancy of TFIIB on a subset of genes (Figure 3A, B, C, D, E, F and G),  
161 suggesting that DOT1L play a general role in the regulation of transcriptional initiation.

162

#### 163 ***DOT1L recruits TFIID via physical interactions***

164 Mechanistically, DOT1L may regulate transcriptional initiation via physical interactions with  
165 initiation factors or creating binding sites for them by methylating H3K79. Pulldown assays using  
166 synthesized short H3 fragments harboring methylated K79 to identify binders of H3K79  
167 methylation were known to be unspecific because of the hydrophobic nature of the fragments.  
168 We therefore chose to understand mechanisms underlying DOT1L-mediated transcriptional  
169 initiation by unbiased analysis of its interacting proteins. To this end, we performed large-scale  
170 co-immunoprecipitation (co-IP) using a DOT1L antibody with nuclear extract from K562 cells,  
171 and characterized immunoprecipitated proteins by mass spectrometry (Figure 4A). Besides  
172 subunits of DOT1L complex, we also identified several TAFs, TFIIH, hSAGA complex, Mediator,  
173 etc. which were previously unknown to interact with DOT1L (Figure 4B). The identification of  
174 TAFs raised a possibility that DOT1L may regulate the recruitment of TFIID via physical  
175 interactions. The confirmation of the interaction between DOT1L and TAF7 by co-IP  
176 experiments from both directions suggested that likely to be the case (Figure 4C and D). We  
177 were also able to confirm the interaction between DOT1L complex and Mediator by co-IP  
178 experiments from both directions, further supporting a role of DOT1L in transcriptional initiation  
179 (Figure 4E and F).

180

### 181 ***ENL regulates transcriptional initiation in human cells***

182 ENL/AF9 are shared subunits between DOT1L complex and SEC, and are capable of  
183 recruiting the two complexes to chromatin by binding to acetylated H3 through their YEATS  
184 domains<sup>22,23</sup>. In addition, ENL has been shown to affect the chromatin occupancy of Pol II and  
185 regulate PPRP as one of the subunits of SEC<sup>23</sup>. Our discovery of DOT1L as a general  
186 regulator of transcriptional initiation in this study and a previously discovered role of ENL in  
187 DOT1L recruitment raised a possibility that ENL may also regulate transcriptional initiation. To  
188 test this idea, we performed CHIP-seq experiments for TBP in control and ENL KO K562 cells  
189 generated by the CRISPR-Cas9 technique (Figure 5A). The loss of ENL markedly reduced the



190 global occupancy of TBP (Figure 5B, C, D and E), supporting a general role in the regulation  
191 transcriptional initiation. The next question we asked was if ENL regulates productive  
192 elongation. To test this idea, we performed 4sUDRB-seq experiments in control and ENL KO  
193 cells, and found that ENL KO minimally affected the productive elongation rate of Pol II (Figure  
194 5F, G, H, I and J). Altogether, these data suggested that in addition to a recognized role in the  
195 regulation of PPRP, ENL also regulates transcription initiation but may not play a major role  
196 in productive elongation.

197

### 198 ***Neither DOT1L nor ENL affects global chromatin accessibility***

199 H3K79 methylation is globally associated with active genes and a conformation change of  
200 H3 is required for the methylation of K79 by DOT1L<sup>25</sup>, which raised a possibility that DOT1L  
201 may regulate global chromatin accessibility and therefore transcriptional initiation. To test this  
202 idea, we perform ATAC-seq in control, DOT1L KO and ENL KO K562 cells. We found that the  
203 DOT1L KO slightly increased global chromatin accessibility but ENL KO had no effect on it  
204 (Figure 6A and B). A closer examination of the peaks uncovered that DOT1L KO slightly  
205 decreased the percentage of peaks on promoters, but ENL KO exhibited little effect (Figure 6C).  
206 However, further analyses revealed no global reduction of promoter accessibility after DOT1L or  
207 ENL KO but an expected positive correlation between promoter accessibility and mRNA level  
208 change (Figure 6D). Altogether, these data suggested that although H3K79 methylation is  
209 associated with active genes, neither DOT1L nor ENL affects global chromatin accessibility.

210

211 To further understand the relationships among DOT1L KO, TBP occupancy and promoter  
212 accessibility, we divided promoters into five groups according to their values of accessibility  
213 changes after DOT1L KO and compared their TBP occupancy changes. As expected, TBP  
214 occupancy was found to be positively correlated with promoter accessibility (Figure 6E). Notably,  
215 we also found that even promoters with increased accessibility exhibited decreased

216 occupancies of TBP after DOT1L KO (Figure 6E), strongly supporting a DOT1L dependency of  
217 TFIIID recruitment regardless of promoter accessibility change.

218

### 219 ***DOT1L promotes H2Bub1 by limiting the recruitment of hSAGA complex***

220 In both yeast and metazoans, H2Bub1 is required for H3K79 methylation by Dot1. SAGA  
221 complex is known to catalyze H3 acetylation, in particular H3K9 and H3K27 acetylation, and  
222 H2B deubiquitination. In yeast, Dot1 was found to promote H2Bub1 by limiting the recruitment of  
223 SAGA complex in an enzymatic activity independent manner<sup>26</sup>, in *C. elegans*, DOT-1.1 was  
224 found to suppress H2Bub1<sup>27</sup>, but the effect and the underlying mechanisms in human cells are  
225 undetermined. The identification of human SAGA (hSAGA) complex in our DOT1L  
226 immunoprecipitants led us to study this matter. The interaction between DOT1L and hSAGA  
227 complex was confirmed by co-IP experiments from both directions (Figure 7A and B). To  
228 determine if DOT1L affects the recruitment of hSAGA complex and H2Bub1, we performed  
229 ChIP-seq experiments for PCAF, a subunit of the acetyltransferase module of hSAGA complex,  
230 and H2Bub1 in control and DOT1L KO K562 cells. Consistent with the results in yeast, the loss  
231 of DOT1L increased the chromatin occupancy of PCAF but decreased global H2Bub1 (Figure  
232 7C, D, and E). We noted that the quality of the PCAF ChIP-seq was not high. To confirm the  
233 results, we performed CUT&Tag for PCAF in control and DOT1L KO cells, and got the same  
234 results (Figure 7F and G). Taken together, these data suggested that in human cells, DOT1L  
235 promote H2Bub1 by limiting the recruitment of hSAGA complex likely through physical  
236 interactions.

237

## 238 **DISCUSSION**

239 DOT1L normally forms a complex with AF10, AF17 and ENL/AF9, is considered an  
240 elongation factor without sufficient evidence, and is dysregulated in most of the cases of MLL  
241 with incompletely understood mechanisms. In this study, we provide results suggesting that

242 DOT1L complex actually regulates transcriptional initiation by facilitating the recruitment of  
243 TFIID and that DOT1L promotes H2Bub1 by limiting the recruitment of hSAGA complex (Figure  
244 7H).

245

#### 246 ***DOT1L complex regulates transcriptional initiation***

247 DOT1L was considered an elongation factor for association with Pol II, sharing ENL/AF9  
248 subunits with SEC, a critical elongation complex, and the localization of H3K79me2 on the  
249 bodies of active genes. By analyzing both traveling ratio and elongation rate of Pol II, we found  
250 that DOT1L is unlikely to play a major role in PPPRP and productive elongation in human cells  
251 with the conclusion related to PPPRP in agreement with that of a recent published study using  
252 mouse ES cells <sup>29</sup>. By analyzing GTFs binding and their interactions with DOT1L, we found that  
253 DOT1L actually regulates global transcriptional initiation likely through physical interactions with  
254 GTFs. In addition, we found that ENL, one of the shared subunits of SEC and DOT1L complex  
255 that have been reported to be able to recruit DOT1L by binding acetylated H3 <sup>23</sup>, also regulates  
256 global transcriptional initiation but not productive elongation. Altogether, our results defined  
257 DOT1L complex as a general regulator of transcriptional initiation although the molecular details  
258 need further investigation.

259

#### 260 ***DOT1L stimulates H2Bub1 by limiting the recruitment of hSAGA complex***

261 In both yeast and metazoans, H2Bub1 is required for H3K79 methylation by providing  
262 binding site for Dot1/Dot1L. In yeast, Dot1 was found to promote H2Bub1 by limiting the  
263 recruitment of SAGA complex in an enzymatic activity independent manner <sup>26</sup>, in *C. elegans*,  
264 DOT-1.1 was found to suppress H2Bub1 <sup>27</sup>, but the effect and the underlying mechanisms in  
265 human cells were undetermined. In the yeast, the role of SAGA complex in transcriptional  
266 initiation has been well-established <sup>5,6</sup>, but it is less clear why some of the promoters are TFIID  
267 dependent and others are SAGA dependent. In contrast, the SAGA complex was found to play

268 a post initiation role in metazoans<sup>7</sup>. We found that DOT1L promotes H2Bub1 by limiting the  
269 recruitment of hSAGA complex, which not only is in agreement with the conclusion in yeast but  
270 also suggests that the connection between the two complexes is likely to be evolutionarily  
271 conserved. Our results also raised a possibility that Dot1 may facilitate the choose between  
272 TFIID and SAGA complex for transcriptional initiation at least in yeast. Nevertheless, the  
273 functional significance and the molecular details of this connection remain to be elucidated.

274

### 275 ***MLL-FPs promote transcriptional initiation through DOT1L complex***

276 MLL-FPs are known to induce MLL by maintaining the expression of several key target  
277 genes, most notably *HOXA9* and *MES11*, which normally are highly expressed in hematopoietic  
278 progenitor cells for promoting proliferation and protection from stress<sup>32,33</sup>. Considering that  
279 major fusion partners of MLL1 are subunits of either SEC or DOT1L complex, that SEC is a  
280 critical elongation factor and DOT1L was considered an elongation factor, MLL-FPs were  
281 believed to achieve so by stimulating transcriptional elongation. Our discovery of DOT1L  
282 complex as a general regulator of transcriptional initiation suggests that MLL-FPs are likely able  
283 to stimulate transcriptional initiation and elongation. The binding to CpG islands near promoters  
284 via the CXXC domain within their MLL1 N-terminus fragments and the stimulation of  
285 transcriptional initiation and elongation by recruiting DOT1L complex and P-TEFb, respectively,  
286 enable MLL-FPs to efficiently maintain the expression of key target genes.

287

288

289 **METHODS**

290 ***Cells and cell culture***

291 Human cells HEL, THP1, and MOLM-13 cells were cultured in RPMI-1640 + 10% FBS + 2%  
292 Penicillin/Streptomycin + 2 mM L-Glutamine + 55  $\mu$ M  $\beta$ -mercaptoethanol. Human cells K562  
293 were cultured in 90% DMEM + 10% FBS+ 2% Penicillin/Streptomycin + 2 mM L-Glutamine.

294

295 ***CUT&Tag and data analyses***

296 CUT&Tag experiments were performed as previously described with minor modifications <sup>34</sup>.  
297 Briefly, 100,000 cells were used for each experiment. Cells were bound to Concanavalin A-  
298 coated beads without fixation and chromatin opening. After primary and secondary antibodies  
299 binding, pA-Tn5 transposome binding, and tagmentation, DNA was extracted and amplified by  
300 PCR. Raw reads were filtered using fastp <sup>35</sup> (version 0.13.1, default parameters) and aligned  
301 using Bowtie2 <sup>36</sup> (version 2.3.4.1) to Bowtie2 index based on hg38 downloaded from NCBI.  
302 Low-quality alignments were filtered out using SAMtools <sup>37</sup> (version 0.1.19) with command  
303 “samtools view -F 1804 -q 25”. MarkDuplicates tools in Picard <sup>38</sup> was used to identify and  
304 remove PCR duplicates from the aligned reads. We used bamCoverage from deepTools <sup>39</sup>  
305 (version 3.3.1) to calculate read coverage per 50-bp bin using the CPM normalization option.  
306 Heatmaps were generated using computeMatrix and plotHeatmap, and meta-gene profile plots  
307 were generated using computeMatrix and plotProfile from deepTools.

308

309 ***Accession numbers***

310 Next generation sequencing data have been submitted to GEO repository under accession  
311 number GSE161367.

312

313 **ACKNOWLEDGEMENTS**

314 The authors would like to thank H. Jiang (UVA) for critical reading of the manuscript. R.G.R.  
315 is supported by a Leukemia and Lymphoma Society SCOR grant, and M.Y. is supported by  
316 grants from The Program for Professor of Special Appointment (Eastern Scholar) at Shanghai  
317 Institutions of Higher Learning, and National Natural Science Foundation of China (31671351).

318

319 **AUTHOR CONTRIBUTIONS**

320 M.Y. and R.G.R. designed the experiments, J.Z., T.T., L.C., M.Y., Z.L., and L.F. performed  
321 the experiments and analyzed the data, A.W. performed the bioinformatics analysis, and M.Y.,  
322 A.W. and R.G.R wrote the paper.

323

324 **REFERECES**


- 325 1. Bhagwat, A.S. & Vakoc, C.R. Targeting Transcription Factors in Cancer. *Trends Cancer*  
326 **1**, 53-65 (2015).
- 327 2. Roeder, R.G. 50+ years of eukaryotic transcription: an expanding universe of factors  
328 and mechanisms. *Nat Struct Mol Biol* **26**, 783-791 (2019).
- 329 3. Nogales, E., Louder, R.K. & He, Y. Structural Insights into the Eukaryotic  
330 Transcription Initiation Machinery. *Annu Rev Biophys* **46**, 59-83 (2017).
- 331 4. Koutelou, E., Hirsch, C.L. & Dent, S.Y. Multiple faces of the SAGA complex. *Curr Opin*  
332 *Cell Biol* **22**, 374-82 (2010).
- 333 5. Donczew, R., Warfield, L., Pacheco, D., Erijman, A. & Hahn, S. Two roles for the yeast  
334 transcription coactivator SAGA and a set of genes redundantly regulated by TFIID  
335 and SAGA. *Elife* **9**(2020).
- 336 6. Helmlinger, D. & Tora, L. Sharing the SAGA. *Trends Biochem Sci* **42**, 850-861 (2017).
- 337 7. Weake, V.M. et al. Post-transcription initiation function of the ubiquitous SAGA  
338 complex in tissue-specific gene activation. *Genes Dev* **25**, 1499-509 (2011).
- 339 8. Adelman, K. & Lis, J.T. Promoter-proximal pausing of RNA polymerase II: emerging  
340 roles in metazoans. *Nat Rev Genet* **13**, 720-31 (2012).
- 341 9. Vos, S.M. et al. Structure of activated transcription complex Pol II-DSIF-PAF-SPT6.  
342 *Nature* **560**, 607-612 (2018).
- 343 10. Yu, M. et al. RNA polymerase II-associated factor 1 regulates the release and  
344 phosphorylation of paused RNA polymerase II. *Science* **350**, 1383-6 (2015).
- 345 11. Peterlin, B.M. & Price, D.H. Controlling the elongation phase of transcription with P-  
346 TEFb. *Mol Cell* **23**, 297-305 (2006).
- 347 12. Smith, E., Lin, C. & Shilatifard, A. The super elongation complex (SEC) and MLL in  
348 development and disease. *Genes Dev* **25**, 661-72 (2011).
- 349 13. Lu, H. et al. Gene target specificity of the Super Elongation Complex (SEC) family:  
350 how HIV-1 Tat employs selected SEC members to activate viral transcription.  
351 *Nucleic Acids Res* **43**, 5868-79 (2015).
- 352 14. Krivtsov, A.V. & Armstrong, S.A. MLL translocations, histone modifications and  
353 leukaemia stem-cell development. *Nat Rev Cancer* **7**, 823-33 (2007).
- 354 15. Ernst, P. & Vakoc, C.R. WRAD: enabler of the SET1-family of H3K4  
355 methyltransferases. *Brief Funct Genomics* **11**, 217-26 (2012).
- 356 16. Lauberth, S.M. et al. H3K4me3 interactions with TAF3 regulate preinitiation  
357 complex assembly and selective gene activation. *Cell* **152**, 1021-36 (2013).
- 358 17. Bernt, K.M. et al. MLL-rearranged leukemia is dependent on aberrant H3K79  
359 methylation by DOT1L. *Cancer Cell* **20**, 66-78 (2011).
- 360 18. Wang, X., Chen, C.W. & Armstrong, S.A. The role of DOT1L in the maintenance of  
361 leukemia gene expression. *Curr Opin Genet Dev* **36**, 68-72 (2016).
- 362 19. Wood, K., Tellier, M. & Murphy, S. DOT1L and H3K79 Methylation in Transcription  
363 and Genomic Stability. *Biomolecules* **8**(2018).
- 364 20. Chen, C.W. et al. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain  
365 leukemic gene expression in MLL-rearranged leukemia. *Nat Med* **21**, 335-43 (2015).
- 366 21. Deshpande, A.J. et al. AF10 regulates progressive H3K79 methylation and HOX gene  
367 expression in diverse AML subtypes. *Cancer Cell* **26**, 896-908 (2014).
- 368 22. Li, Y. et al. AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79  
369 methylation. *Cell* **159**, 558-71 (2014).

- 370 23. Wan, L. et al. ENL links histone acetylation to oncogenic gene expression in acute  
371 myeloid leukaemia. *Nature* **543**, 265-269 (2017).
- 372 24. Kim, S.K. et al. Human histone H3K79 methyltransferase DOT1L protein [corrected]  
373 binds actively transcribing RNA polymerase II to regulate gene expression. *J Biol*  
374 *Chem* **287**, 39698-709 (2012).
- 375 25. Worden, E.J. & Wolberger, C. Activation and regulation of H2B-Ubiquitin-dependent  
376 histone methyltransferases. *Curr Opin Struct Biol* **59**, 98-106 (2019).
- 377 26. van Welsem, T. et al. Dot1 promotes H2B ubiquitination by a methyltransferase-  
378 independent mechanism. *Nucleic Acids Res* **46**, 11251-11261 (2018).
- 379 27. Cecere, G., Hoersch, S., Jensen, M.B., Dixit, S. & Grishok, A. The ZFP-1(AF10)/DOT-1  
380 complex opposes H2B ubiquitination to reduce Pol II transcription. *Mol Cell* **50**, 894-  
381 907 (2013).
- 382 28. Feng, Y. et al. Early mammalian erythropoiesis requires the Dot1L  
383 methyltransferase. *Blood* **116**, 4483-91 (2010).
- 384 29. Cao, K. et al. DOT1L-controlled cell-fate determination and transcription elongation  
385 are independent of H3K79 methylation. *Proc Natl Acad Sci U S A* (2020).
- 386 30. Rahl, P.B. et al. c-Myc regulates transcriptional pause release. *Cell* **141**, 432-45  
387 (2010).
- 388 31. Fuchs, G. et al. 4sUDRB-seq: measuring genomewide transcriptional elongation rates  
389 and initiation frequencies within cells. *Genome Biol* **15**, R69 (2014).
- 390 32. Unnisa, Z. et al. Meis1 preserves hematopoietic stem cells in mice by limiting  
391 oxidative stress. *Blood* **120**, 4973-81 (2012).
- 392 33. Lawrence, H.J. et al. Loss of expression of the Hoxa-9 homeobox gene impairs the  
393 proliferation and repopulating ability of hematopoietic stem cells. *Blood* **106**, 3988-  
394 94 (2005).
- 395 34. Kaya-Okur, H.S. et al. CUT&Tag for efficient epigenomic profiling of small samples  
396 and single cells. *Nat Commun* **10**, 1930 (2019).
- 397 35. Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor.  
398 *Bioinformatics* **34**, i884-i890 (2018).
- 399 36. Langmead, B. & Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. *Nat*  
400 *Methods* **9**, 357-9 (2012).
- 401 37. Li, H. et al. The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**,  
402 2078-9 (2009).
- 403 38. Institute, B. Picard Toolkit. in *Broad Institute, GitHub repository* (2019).
- 404 39. Ramirez, F. et al. deepTools2: a next generation web server for deep-sequencing  
405 data analysis. *Nucleic Acids Res* **44**, W160-5 (2016).
- 406
- 407



408  
409


## FIGURES



410

411


412 **Figure 1. DOT1L promotes the chromatin association of Pol II in human cells.** (A) and (B)  
413 Comparison of the occupancies of total Pol II (A) and Pol II (ser-2p) (B) on an average gene in  
414 DOT1L KD versus control HEL cells by ChIP-seq. (C) Normalized read distribution of total and  
415 ser2-phosphorylated Pol II ChIP-seq experiments within the *c-MYC* locus in DOT1L KD versus  
416 control HEL cells. (D) Characterization of a DOT1L KO K562 cell line by Western blot. (E)  
417 Comparison of total Pol II occupancies on an average gene in control and DOT1L KO cells. (F)  
418 Normalized read distribution of total Pol II ChIP-seq within the *c-MYC* locus in DOT1L KO  
419 versus control K562 cells. (G) Comparison of the mRNA level of *HOXA9* in DMSO and  
420 SGC0946 treated THP1 cells by qRT-PCR. (H) and (I) Comparison of DOT1L (H) and total Pol  
421 II (I) occupancies within the *HOXA9* locus in DMSO and SGC0946 treated THP1 cells by ChIP  
422 followed by qPCR. (J) Comparison of the mRNA levels of *HOXA9* and *MEIS1* in DMSO and  
423 SGC0946 treated MOLM-13 cells by qRT-PCR. (K) and (L) Comparison of DOT1L (K) and total  
424 Pol II (L) occupancies within the *HOXA9* and *MEIS1* loci in DMSO and SGC0946 treated  
425 MOLM-13 cells by ChIP followed by qPCR.  
426  
427




428

429

430 **Figure 2. DOT1L may not play a major role in transcriptional elongation in human cells.**  
431 (A) Schematic representation describing the calculation used to determine the traveling ratio  
432 (TR) at each Pol II-bound gene. (B) Comparison of the TR of total Pol II in control and DOT1L  
433 KD HEL cells. (C) Comparison of the TR of total Pol II in control and DOT1L KO K562 cells. (D)  
434 Comparison of the distribution of engaged Pol II near TSSs in control and DOT1L KD HEL cells  
435 by PRO-seq. (E) Normalized read distribution of PRO-seq within the *c-MYC* locus in DOT1L KD  
436 versus control HEL cells. (F) Comparison of the TR of engaged Pol II in control and DOT1L KD  
437 HEL cells. (G) Normalized read distribution of 4sUDRB-seq experiments comparing Pol II  
438 elongation rate of *UVRAG* in DOT1L KO versus control K562 cells. (H) HMM model of  
439 elongation rate calculation for *UCRAG* in control and DOT1L KO K562 cells. (I) Range of Pol II  
440 elongation rate on genes in control and DOT1L KO K562 cells. (J) Pol II elongation rate change  
441 in DOT1L KO versus control K562 cells. (K) A volcano plot of genes with Pol II elongation rate  
442 changes in DOT1L KO versus control K562 cells.  
443  
444




446 **Figure 3. DOT1L regulates transcriptional initiation in human cells.** (A), (B) and (C)  
447 Genome-wide meta-gene profiles and heatmaps of ChIP-seq comparing the chromatin  
448 occupancies of TBP (A), TFIIA (B) and TFIIIB (C) in DOT1L KO versus control K562 cells. (D)  
449 Normalized read distribution of ChIP-seq experiments comparing the occupancy of TBP, TFIIA,  
450 and TFIIIB within the *c-MYC* locus in DOT1L KO versus control K562 cells. (E), (F) and (G)  
451 Occupancy changes of TBP (E), TFIIA (F) and TFIIIB (G) on promoters. Left panels, Dot and  
452 density plots of occupancy changes on promoters in two replicates. Consistency between the  
453 replicates was measured by Pearson correlation coefficient. Right panels, MA plots of  
454 differential occupancy on promoters based on the replicates.  
455



456  
 457 **Figure 4. DOT1L interacts with transcriptional initiation factors.** (A) Silver stain of proteins  
 458 immunoprecipitated by rabbit IgG and a DOT1L antibody, respectively, and separated on an  
 459 SDS-PAGE gel. (B) Protein complexes co-immunoprecipitated with DOT1L. (C) WB analyses of  
 460 TFIIID subunits co-immunoprecipitated with DOT1L. (D) WB analyses of DOT1L complex  
 461 subunits co-immunoprecipitated with TAF7. (E) WB analyses of Mediator subunits co-  
 462 immunoprecipitated with DOT1L. (F) WB analyses of subunits of DOT1L complex co-  
 463 immunoprecipitated with MED1 and MED15.

464  
 465




466

467




468 **Figure 5. ENL regulates transcriptional initiation in human cells.** (A) Characterization of an  
469 ENL KO K562 cell line by Western blot. (B) Genome-wide meta-gene profiles and heatmaps of  
470 ChIP-seq comparing the chromatin occupancies of TBP in ENL KO versus control K562 cells.  
471 (C) Normalized read distribution of ChIP-seq comparing the occupancy of TBP within the *c-MYC*  
472 locus in ENL KO versus control K562 cells. (D) A dot and density plot of TBP occupancy change  
473 on promoters in two replicates. Consistency between the replicates was measured by Pearson  
474 correlation coefficient. (E) An MA plot of differential occupancy on promoters calculated with the  
475 replicates. (F) Normalized read distribution of 4sUDRB-seq experiments comparing the Pol II  
476 elongation rate of *UVRAG* in ENL KO versus control K562 cells. (G) HMM model of Pol II  
477 elongation rate calculation for *UCRAG* in control and ENL KO K562 cells. (H) Range of Pol II  
478 elongation rate in control and ENL KO K562 cells. (I) Pol II elongation rate changes in ENL KO  
479 versus control K562 cells. (J) A volcano plot of genes with Pol II elongation rate changes in ENL  
480 KO versus control K562 cells.  
481  
482



483

484

485 **Figure 6. Neither DOT1L nor ENL affects global chromatin accessibility.** (A) Venn diagram  
486 showing overlaps among peaks identified from control, DOT1L KO and ENL KO cells,  
487 respectively. The consensus peak set was obtained by merging peaks from all the cell lines. (B)  
488 Chromatin accessibility around consensus peak centers in control, DOT1L KO and ENL KO  
489 cells. (C) Genomic feature annotation of ATAC-seq peaks identified in control, DOT1L KO cells,  
490 ENL KO cells and the consensus peak set. (D) Promoter accessibility changes of differentially  
491 expressed genes in control, DOT1L KO and ENL KO cells. Top, Promoter accessibility changes  
492 of up-regulated, down-regulated and genes without significant change. Bottom, Scatter plots of  
493 gene expression change versus promoter accessibility change. Pearson's correlation coefficient  
494 was labeled on top left. (E) Box and jitter plots of TBP occupancy change on promoters grouped  
495 by degree of accessibility changes in control, DOT1L KO and ENL KO cells.  
496  
497




498

499

500 **Figure 7. DOT1L promotes H2Bub1 by limiting the recruitment of hSAGA complex.** (A)  
501 WB analyses of subunits of hSAGA complex co-immunoprecipitated with DOT1L. (B) WB  
502 analyses of subunits of DOT1L complex co-immunoprecipitated with TRRAP. (C) and (D)  
503 Genome-wide meta-gene profiles and heatmaps of ChIP-seq comparing the occupancies of  
504 PCAF (C) and H2Bub1 (D) in DOT1L KO versus control K562 cells. (E) Normalized read  
505 distribution of ChIP-seq comparing the occupancy of PCAF and H2Bub1 within the *TMEM18*  
506 locus in DOT1L KO versus control K562 cells. (F) Genome-wide meta-gene profiles and  
507 heatmaps of CUT&Tag comparing the occupancies of PCAF in DOT1L KO versus control K562  
508 cells. (G) Normalized read distribution of CUT&Tag comparing the occupancy of PCAF within  
509 the *TMEM18* locus in DOT1L KO versus control K562 cells. (H) Working model of this study.  
510 The ENL subunit of DOT1L complex binds acetylated H3 and recruits DOT1L, DOT1L complex  
511 regulates transcriptional initiation likely by recruiting TFIID. DOT1L promotes H2Bub1 by limiting  
512 the recruitment of hSAGA complex, which contains a deubiquitinase module.  
513

514 **SUPPLEMENTARY INFORMATION**

515 **SUPPLEMENTARY FIGURES**



516

517 **Figure S1. DOT1L KD reduced the chromatin occupancy of Pol II in HEL cells. (A)**


518 Comparison of the levels of DOT1L, Pol II (ser-5p) and Pol II (ser-2p) in control versus DOT1L

519 KD HEL cells by Western blot. β-ACTIN was used as a loading control. (B), (C), (D), and (E)

520 Comparison of the occupancies of DOT1L (B), Pol II (ser-2p) (C), total Pol II (D), and Pol II (ser-

521 5p) (E) on *c-MYC* and *CTNNB1* by ChIP-qPCR in control versus DOT1L KD HEL cells.

522




523

524 **Figure S2. DOT1L KD affected the transcription of a subset of genes in HEL cells. (A) A**

525 volcano plot of differentially expressed genes in control and DOT1L KD HEL cells. (B) A

526 heatmap of differentially expressed genes in control and DOT1L KD HEL cells.

527



528

529 **Figure S3. DOT1L KO affected the transcription of a subset of genes in K562 cells. (A) A**

530 volcano plot of differentially expressed genes in control and DOT1L KO K562 cells. (B) A

531 heatmap of differentially expressed genes in control and DOT1L KO K562 cells.

532



533 **SUPPLEMENTARY TABLES**

534 **Table S1. Primers for qRT-PCR.**

<b>Name</b>	<b>Primer sequence (5' to 3')</b>
HOXA9 Forward	CCACGCTTGACACTCACACT
HOXA9 Reverse	CAGTTCCAGGGTCTGGTGTT
MEIS1 Forward	AAGGTGATGGCTTGGACAAC
MEIS1 Reverse	TGTGCCAACTGCTTTTTCTG

535

536

537 **Table S2. Guide RNAs.**

<b>Name</b>	<b>Sequence</b>
ENL Forward	CACCGGAGCTTGTACCGGAACTCCG
ENL Reverse	AAACCGGAGTTCCGGTACAAGCTCC
DOT1L Forward	CACCGCTGAGACTGAAGTCGCCCGT
DOT1L Reverse	AAACACGGGCGACTTCAGTCTCAGC

538

539

540 **Table S3. Antibodies.**

<b>Target</b>	<b>Vender</b>	<b>Catalogue number</b>	<b>Applications</b>
DOT1L	Bethyl	A300-953A	WB
DOT1L	Cell Signaling	77087S	WB, IP
Pol II	Santa Cruz	sc-899	WB, ChIP
ser-2 phosphorylated Pol II	Active Motif	61083	WB
ser-5 phosphorylated Pol II	Active Motif	61085	WB
TBP	Santa Cruz	sc-56795	WB, ChIP
GTF2A2	Proteintech	10540-1-AP	WB, ChIP
TFIIB	Proteintech	16467-1-AP	WB, ChIP
H3K79me2	Abcam	ab3594	WB
TAF7	Proteintech	13506-1-AP	WB, IP
MED1	Bethyl	A300-793A	WB, IP
MED27	Santa Cruz	sc-390296	WB
MED15	Proteintech	11566-1-AP	WB, IP
MED12	Proteintech	20028-1-AP	WB
MED14	ABclonal	A10455	WB
MED20	ABclonal	A15757	WB
ENL	Santa Cruz	sc-393196	WB
TRRAP	Abcam	ab183517	WB, IP
TADA3L	Proteintech	10839-1-AP	WB
H2Bub1	Active Motif	39623	ChIP
PCAF	Abcam	ab12188	ChIP, CUT&Tag
AF10	Santa Cruz	sc-53156	WB
GCN5	ABclonal	A2224	WB

541

542

543 **Table S4. Primers for ChIP-qPCR.**

<b>Name</b>	<b>Primer sequence (5' to 3')</b>
NANOG Forward	GAATGAGCAAGTGGGGATGT
NANOG Reverse	CCCCTGCAGTCACATAACAA
MYC-TSS Forward	GGCACTTTGCACTGGAAGTT
MYC-TSS Reverse	GGTGCTTACCTGGTTTTCCA
MYC-(+)2 kb Forward	GATAGCAGGGGACTGTCCAA
MYC-(+)2 kb Reverse	CGGGAGGCAGTCTTGAGTTA
CTNNB1 Forward	TTAAGCCTCTCGGTCTGTGG
CTNNB1 Reverse	AGGATAAGGAAAGGAGCGCC
HOXA9-(-)3.7 kb Forward	ACACACCTCCACCTGGTCAC
HOXA9-(-)3.7 kb Reverse	CCAAAGCCCAGAATTCCTAC
HOXA9-(+)0.5 kb Forward	CGGATTTGAAGGGAGGAGAC
HOXA9-(+)0.5 kb Reverse	CCACGCTTGACACTCACACT
HOXA9-(+)2.3 kb Forward	CACAATCACAATGGGTGCAT
HOXA9-(+)2.3 kb Reverse	TGCACAAGTGTGATGGTAGG
MEIS1-(+)2.4 kb Forward	TCTGCACTCGCATCAGTACC
MEIS1-(+)2.4 kb Reverse	CAAGGGCACAGAGAAAGAGG

544

545

546 **SUPPLEMENTARY METHODS**

547 ***RNA interference, RNA extraction, reverse transcription, real-time PCR, RNA-seq and***  
548 ***data analyses***

549 pLKO.1 TRC control and mission shRNA clones were purchased from Sigma Aldrich. For  
550 lentivirus production and transduction, 60-90% confluent 293T cells in antibiotic-free medium  
551 were transfected on day 1 with TRC control or gene-specific shRNA clones along with  
552 packaging plasmids psPAX2 and pMD2.G. On day 2 in the morning, medium containing  
553 transfection reagent was replaced by fresh medium containing 2% Penicillin-Streptomycin  
554 (Sigma Aldrich, cat. no. P0781). On day 3 in the afternoon, cells were resuspended in virus-  
555 containing medium, and spun at 2,000 rpm at 20 °C for 1 hour. After spin infection, virus-  
556 containing medium was removed and cells were resuspended in fresh medium and cultured  
557 overnight. On day 4 in the morning, cells were washed twice with PBS and resuspended in fresh  
558 medium. On day 5 in the morning, puromycin was added to a final concentration of 2 µg/ml.  
559 Cells were cultured for additional 72 hours before being harvested for qRT-PCR, Western blot,  
560 and ChIP. Mission shRNA clone and qRT-PCR primers used in this study are listed in Table S1.  
561

562 *RNA was extracted from cells using RNeasy Plus Mini Kit (Qiagen, cat. no. 74134) and*  
563 *Quick-RNA MiniPrep Kit (Zymo Research, cat. no. R1054) by following the manufacturers'*  
564 *protocols. Libraries of strand-specific RNA-seq were constructed as previously described*<sup>40</sup>.  
565 *Raw reads were filtered using fastp*<sup>35</sup> *(version 0.13.1, default parameters) and mapped to hg38*  
566 *using HISAT2*<sup>41</sup> *(version 2.1.0) with parameters "--rna-strandness RF -dta". Read counts per*  
567 *gene were calculated in strand-specific manner using featureCounts*<sup>42</sup>. *For each RNA-seq*  
568 *library, reads were mapped with overall mapping rate of ~97%. Differential expression analysis*  
569 *were performed using DESeq2*<sup>43</sup>, *and genes with adjusted p value < 0.05 and fold change of >*  
570 *2 were identified as significantly differentially expressed.*

571

572 ***Generation of knockout cell lines by CRISPR/Cas9***

573 A K562-derived cell line inducibly expressing Cas9, K562-iCas9, was generated by  
574 transducing pCW-Cas9-Hygro into K562 cells and selecting clones with high-level expression.  
575 Guide RNAs (gRNAs) were designed using the tool provided by Benching, cloned into  
576 lentiGuide-Puro, individually transduced into K562-iCas9 cells. Single colonies obtained by  
577 serial dilution were expanded and subsequently characterized by Western blot. Sequences of  
578 gRNAs used in this study are listed in Table S2.

579

580 ***ChIP, ChIP-sequencing (ChIP-seq) and data analysis***

581 ChIP assays were performed as previously described<sup>44</sup>. Normally, cells were fixed with  
582 0.4% (v/v) formaldehyde at room temperature for 10 min. To improve the ChIP efficiency,  
583 double fixation was used. For double fixation with EGS (Thermo, cat. no. 21565) and  
584 formaldehyde, cells were fixed initially with 1.5 mM EGS at room temperature for 30 min, and  
585 subsequently with 0.4% formaldehyde at room temperature for 10 min. For double fixation with  
586 DMA (Thermo, cat. no. 20660) and formaldehyde, cells were fixed initially with 25 mM DMA at  
587 room temperature for 1 hour, and subsequently with 0.4% formaldehyde at room temperature  
588 for 10 min. For sonication, fixed cells were washed twice with PBS and resuspended in ice-cold  
589 RIPA-0.3 buffer (10 mM Tris-HCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, 0.1% NaDOC, and  
590 0.3 M NaCl, pH 7.4) supplemented with Protease Inhibitor Cocktail (Millipore, cat. no. 535140)  
591 at a concentration of 40 million cells/ml; genomic DNA was disrupted to a size range of 100 to  
592 500 bp. For immunoprecipitation, on day 1 antibodies were diluted in RIPA-0.3 and bound to  
593 Dynabeads protein A (Thermo, cat. no. 10002D) by incubating at 4 °C for 3 hours. Afterwards,  
594 the bead-antibody complexes were washed twice with RIPA-0.3 and then incubated with  
595 sonicated chromatin at 4 °C overnight. On day 2, after 2 washes with RIPA-0.5, 1 wash with

596 RIPA-0.3, 1 wash with RIPA-0, 2 washes with LiCl buffer (10 mM Tris-HCl, 1 mM EDTA, 0.25 M  
597 LiCl, 0.25% NP-40, and 0.25% NaDOC, pH 7.4), and 2 washes with TE buffer, bound protein-  
598 DNA complexes were resuspended in elution buffer (10 mM Tris-HCl, 1mM EDTA, 0.2 M NaCl,  
599 and 1% SDS, pH 7.4) supplemented with 10 µg/ml RNase A for both elution and RNA digestion,  
600 and incubated at 55 °C for 1 hour. Then Proteinase K was added to a final concentration of 200  
601 µg/ml, and after 30 min incubation the temperature was increased to 65 °C for crosslink  
602 reversal. After incubation for 4 to 6 hours, DNA was purified by ChIP DNA Clean & Concentrator  
603 (Zymo Research, cat. no. D5205). For qPCR, a site 2 kb downstream of the TSS of the *NANOG*  
604 gene was used as an internal control, and fold-enrichment was calculated by the  $2^{\Delta Ct}$  method.  
605 The antibodies that were used for ChIP assays are listed in Table S3. Real-time PCR primers  
606 for ChIP are listed in Table S4.

607

608 ChIP-seq libraries were constructed with 2–10 ng immunoprecipitated DNA. After end-  
609 repair, A-tailing, and barcode ligation, barcoded DNA was amplified by 16- to 18-cycle PCR.  
610 Libraries were sequenced on Illumina HiSeq 2000, HiSeq 2500 or HiSeq X Ten by following the  
611 manufacturer's protocols. Raw reads were filtered using fastp<sup>35</sup> (version 0.13.1, default  
612 parameters) and aligned using Bowtie2<sup>36</sup> (version 2.3.4.1) to Bowtie2 index based on hg38  
613 downloaded from NCBI. Low-quality alignments were filtered out using SAMtools<sup>37</sup> (version  
614 0.1.19) with command "samtools view -F 1804 -q 25". MarkDuplicates tools in Picard<sup>38</sup> was  
615 used to identify and remove PCR duplicates from the aligned reads. Peak calling was carried  
616 out using MACS2<sup>45</sup> version 2.2.6 with input control. Broad peaks were called with parameters "-  
617 q 0.01 --broad --nomodel --shift 0 --keep-dup all". We used bamCoverage from deepTools<sup>39</sup>  
618 (version 3.3.1) to calculate read coverage per 50-bp bin using the CPM normalization option.  
619 Heatmaps were generated using computeMatrix and plotHeatmap, and meta-gene profile plots  
620 were generated using computeMatrix and plotProfile from deepTools. To visualize promoter

621 occupancy change of GTFs in MA plot, read counts in promoters overlap with corresponding  
622 broad peaks were used as input of edgeR<sup>46</sup>, and log<sub>2</sub> CPM and log<sub>2</sub> fold-change were  
623 estimated with norm.factors set to be proportional to total mapped read count after removing  
624 duplications. For each gene, promoter and gene body read densities were calculated as read  
625 count normalized by length and sequencing depth, and traveling ratio was calculated as  
626 promoter read density divided by gene body read density for Pol II-bound genes, which were  
627 defined by CPM in promoter larger than 4.

628

### 629 ***PRO-seq and data analyses***

630 PPO-seq experiments were performed as previously described<sup>47</sup>, and the libraries were  
631 sequenced by Illumina HiSeq 2500. Raw reads were filtered using fastp<sup>35</sup> (version 0.13.1,  
632 default parameters) and aligned using Bowtie2<sup>36</sup> (version 2.3.4.1) to Bowtie2 index based on  
633 hg38 downloaded from NCBI. Low-quality alignments were filtered out using SAMtools<sup>37</sup>  
634 (version 0.1.19) with command “samtools view -F 4 -q 10”. Strand-specific meta-gene profiles  
635 were generated using the groHMM package<sup>48</sup> from Bioconductor. Strand-specific read  
636 coverage was calculated using “bedtools genomecov” with “-ibam”, “-bg” and “-strand” options  
637 and normalized by total mapped reads before loading to IGV for visualization.

638

### 639 ***4sUDRB-seq and data analyses***

640 4sUDRB-seq experiments were performed as previously described<sup>31</sup> with minor  
641 modifications. Briefly, 10 million cells were used for each experiment. After DRB (Sigma, cat.  
642 no. D1916) treatment and 4sU (Sigma, cat. no. T4509) incorporation, total RNA was extracted.  
643 After RNA biotinylation and free biotin removal, biotinylated RNA was purified by streptavidin-  
644 coupled Dynabeads (Thermo, cat. no. 11205D). Before library construction, rRNA was depleted  
645 by following a published protocol<sup>49</sup>. Sequencing libraries were constructed by following the



646 Illumina TruSeq RNA Library preparation protocol. 4sU-DRB-seq reads were filtered using fastp  
647 <sup>35</sup> (version 0.13.1, default parameters) and aligned to the human genome hg19 using Bowtie2 <sup>36</sup>  
648 (version 2.3.4.1) with parameter “-N 1”. Only paired reads aligned to the same chromosome, not  
649 to chromosome chrUn\_gI000220 (rRNA) and with alignment scores < 5 were kept using awk.  
650 rRNA percentage was calculated for each sample. Average rRNA percentage is 3.1% for 0 min  
651 samples and 0.24% for 10 min. BamCoverage from deepTools <sup>39</sup> (version 3.3.1) was used to  
652 generate bigwig files of normalized read coverage per 50-bp bin.

653

654 Transcripts were filtered to calculate elongation rate. For each gene, the longest transcript  
655 was chosen, and it was required to have a minimum transcript length of 30 kb and do not  
656 contain other transcription start site (TSS) of this gene. Further filtering was performed to  
657 exclude transcripts overlapping with other genes or within 2 kb from TSSs of another genes.  
658 Finally, 3707 transcripts were kept for calculating elongation rates. Advancing waves were  
659 identified using a three state Hidden Markov Model (HMM) that was previously developed and  
660 implemented on GRO-seq data from a human cell line <sup>50</sup>, in which model, 2kb regions around  
661 TES were not included for the unstable signal in them. Paired t-test was used to test whether  
662 the elongation rate distribution of DOT1L or ENL KO cells is significantly different from that of  
663 control cells for each replicate respectively. Significant faster- or slower elongating genes was  
664 identified using Welch’s t-test based on both two replicates of each cell line.

665

### 666 ***ATAC-seq and data analyses***

667 Tn5 transposase expression and purification, and transposome assembly was conducted as  
668 previously described <sup>51</sup>. ATAC-seq experiments were performed by following a published  
669 protocol <sup>52</sup>. Briefly, 50,000 cells were used for each experiment. After nuclei preparation,  
670 tagmentation, termination and DNA purification, samples were amplified by PCR with one  
671 universal forward primer and different indexed reverse primers. ATAC-seq pair-end reads were

672 filtered using fastp<sup>35</sup> (version 0.13.1, default parameters) and aligned to the human genome  
673 hg38 using Bowtie2<sup>36</sup> (version 2.3.4.1) with parameter “-X 2000”. Samtools was used to filter for  
674 reads mapped to Chr1-22 and ChrX, and MarkDuplicates tools in Picard<sup>38</sup> was used to identify  
675 and remove PCR duplicates from the aligned reads. The final deduplicated BAM file was used  
676 in the downstream analyses.

677

678 Tn5 transposase insertions, which refer to the precise single-base locations where Tn5  
679 transposase accessed the chromatin, were identified by correcting the read start positions by a  
680 constant offset (“+” stranded +4 bp, “-” stranded -5 bp). To generate depth-normalized  
681 accessibility track, bigwig files were constructed based on the Tn5 offset-corrected insertion  
682 sites using GenomicRanges<sup>53</sup> and rtracklayer<sup>54</sup> packages in R. Meta-gene profile plots were  
683 generated using computeMatrix and plotProfile from deepTools<sup>39</sup>. For each replicate, peak  
684 calling was performed on the Tn5-corrected single-base insertions using the “MACS2 callpeak”  
685 command with parameters “-g hs -n Ctrl -q 0.01 --shift -19 --extsize 38 --nomodel --nolambda --  
686 keep-dup all --call-summits”. The peaks were then filtered to remove peaks overlapping hg38  
687 blacklisted region ([http://mitra.stanford.edu/kundaje/akundaje/release/blacklists/hg38-  
688 human/hg38.blacklist.bed.gz](http://mitra.stanford.edu/kundaje/akundaje/release/blacklists/hg38-human/hg38.blacklist.bed.gz)). Consistent peaks of each cell type were called on pooled  
689 replicates, followed by filtering for those displaying at least 50% overlap with any peak from  
690 each of the two single replicate peak sets. Consensus peak set was obtained by merge the  
691 consistent peaks identified in each cell type using command “bedtools merge”. Peak annotation  
692 of consistent peaks of each cell type and the final consensus peak set was performed using  
693 ChIPseeker<sup>55</sup> package in Bioconductor.

694

695 ***Co-immunoprecipitation (co-IP), large scale co-IP, and mass spectrometry***

696 Co-IP assays were performed as previously described with minor modification<sup>56</sup>. Nuclear  
697 extract (NE) from HEL cells was diluted 2 to 3 fold by adding NE dilution buffer. Antibodies were  
698 incubated with Dynabeads protein A at 4 °C for 3 hours, and then cross-linked to beads by 25  
699 mM DMA (Pierce, cat. no. 20660) at room temperature for 1 hour. Normally, 0.5 to 1 mg nuclear  
700 extract was used for each co-IP. After overnight incubation at 4 °C, bead-antibody-protein  
701 complexes were washed with BC-150 buffer (10 mM Tris-HCl, 0.2 mM EDTA, 150 mM KCl,  
702 20% glycerol, and 0.1% NP-40, pH 7.9) for 4 times. The proteins were eluted from beads by 50  
703 mM glycine (pH 2.4), immediately neutralized in 1 M Tris-HCl, pH 7.4, and analyzed by Western  
704 blot. For large-scale co-IP, 10 µg antibody and ~75 mg NE were used for each experiment.  
705 Bead-antibody-protein complexes were washed with BC-200 buffer (10 mM Tris-HCl, 0.2 mM  
706 EDTA, 200 mM KCl, 20% glycerol, and 0.1% NP-40, pH 7.9) for 6 times followed by with 1 x  
707 PBS twice. Eluted proteins were analyzed by a Multidimensional Protein Identification  
708 Technology (MudPIT) system.

709  
710 MS/MS spectra were searched using MASCOT engine (Matrix Science, London, UK;  
711 version 2.2) against the Human UniProt database (downloaded at May 2019; 171145  
712 sequences). For protein identification, the following options were used: Peptide mass  
713 tolerance=20 ppm, MS/MS tolerance=0.1 Da, Enzyme=Trypsin, Missed cleavage=2, Fixed  
714 modification: Carbamidomethyl (C), Variable modification: Oxidation(M) ; score > 20. In total,  
715 1980 and 1960 non-redundant protein were identified in DOT1L-IP and IgG-IP samples,  
716 respectively. Proteins identified in DOT1L-IP sample were filtered by: 1) Unique peptide count of  
717 a protein in IgG-IP sample ( $UPC_{IgG}$ ) is no larger than 1; 2) If  $UPC_{IgG}$  of a protein is 0, unique  
718 peptide count of the same protein in DOT1L-IP sample ( $UPC_{DOT1L}$ ) should be at least 2, and if  
719  $UPC_{IgG}$  of a protein is 1,  $UPC_{DOT1L}$  should be at least 3. 677 proteins met the requirement were  
720 referred to as DOT1L-associated proteins. To identify candidate DOT1L-associated complexes,

721 2916 human protein complexes were downloaded from CORUM (version 3.0), which is a  
722 comprehensive resource of mammalian protein complexes, and 157 redundant ones with  
723 duplicated “ComplexName” and “subunits UniProt ID” and 89 complexes containing only one  
724 subunit were filtered out. Out of the remaining 2670 complexes, coverage of 63 were no less  
725 than 70%, and 41/63 were further filtered out for being totally contained by one of the remaining  
726 22 complexes. After manual review and correction, 11 complexes, including DOT1L complex  
727 itself, were considered as reliable DOT1L-associated complexes.  
728

729 **SUPPLEMENTARY REFERENCES**

- 730 1. Bhagwat, A.S. & Vakoc, C.R. Targeting Transcription Factors in Cancer. *Trends Cancer*  
731 **1**, 53-65 (2015).
- 732 2. Roeder, R.G. 50+ years of eukaryotic transcription: an expanding universe of factors  
733 and mechanisms. *Nat Struct Mol Biol* **26**, 783-791 (2019).
- 734 3. Nogales, E., Louder, R.K. & He, Y. Structural Insights into the Eukaryotic  
735 Transcription Initiation Machinery. *Annu Rev Biophys* **46**, 59-83 (2017).
- 736 4. Koutelou, E., Hirsch, C.L. & Dent, S.Y. Multiple faces of the SAGA complex. *Curr Opin*  
737 *Cell Biol* **22**, 374-82 (2010).
- 738 5. Donczew, R., Warfield, L., Pacheco, D., Erijman, A. & Hahn, S. Two roles for the yeast  
739 transcription coactivator SAGA and a set of genes redundantly regulated by TFIID  
740 and SAGA. *Elife* **9**(2020).
- 741 6. Helmlinger, D. & Tora, L. Sharing the SAGA. *Trends Biochem Sci* **42**, 850-861 (2017).
- 742 7. Weake, V.M. et al. Post-transcription initiation function of the ubiquitous SAGA  
743 complex in tissue-specific gene activation. *Genes Dev* **25**, 1499-509 (2011).
- 744 8. Adelman, K. & Lis, J.T. Promoter-proximal pausing of RNA polymerase II: emerging  
745 roles in metazoans. *Nat Rev Genet* **13**, 720-31 (2012).
- 746 9. Vos, S.M. et al. Structure of activated transcription complex Pol II-DSIF-PAF-SPT6.  
747 *Nature* **560**, 607-612 (2018).
- 748 10. Yu, M. et al. RNA polymerase II-associated factor 1 regulates the release and  
749 phosphorylation of paused RNA polymerase II. *Science* **350**, 1383-6 (2015).
- 750 11. Peterlin, B.M. & Price, D.H. Controlling the elongation phase of transcription with P-  
751 TEFb. *Mol Cell* **23**, 297-305 (2006).
- 752 12. Smith, E., Lin, C. & Shilatifard, A. The super elongation complex (SEC) and MLL in  
753 development and disease. *Genes Dev* **25**, 661-72 (2011).
- 754 13. Lu, H. et al. Gene target specificity of the Super Elongation Complex (SEC) family:  
755 how HIV-1 Tat employs selected SEC members to activate viral transcription.  
756 *Nucleic Acids Res* **43**, 5868-79 (2015).
- 757 14. Krivtsov, A.V. & Armstrong, S.A. MLL translocations, histone modifications and  
758 leukaemia stem-cell development. *Nat Rev Cancer* **7**, 823-33 (2007).
- 759 15. Ernst, P. & Vakoc, C.R. WRAD: enabler of the SET1-family of H3K4  
760 methyltransferases. *Brief Funct Genomics* **11**, 217-26 (2012).
- 761 16. Lauberth, S.M. et al. H3K4me3 interactions with TAF3 regulate preinitiation  
762 complex assembly and selective gene activation. *Cell* **152**, 1021-36 (2013).
- 763 17. Bernt, K.M. et al. MLL-rearranged leukemia is dependent on aberrant H3K79  
764 methylation by DOT1L. *Cancer Cell* **20**, 66-78 (2011).
- 765 18. Wang, X., Chen, C.W. & Armstrong, S.A. The role of DOT1L in the maintenance of  
766 leukemia gene expression. *Curr Opin Genet Dev* **36**, 68-72 (2016).
- 767 19. Wood, K., Tellier, M. & Murphy, S. DOT1L and H3K79 Methylation in Transcription  
768 and Genomic Stability. *Biomolecules* **8**(2018).
- 769 20. Chen, C.W. et al. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain  
770 leukemic gene expression in MLL-rearranged leukemia. *Nat Med* **21**, 335-43 (2015).
- 771 21. Deshpande, A.J. et al. AF10 regulates progressive H3K79 methylation and HOX gene  
772 expression in diverse AML subtypes. *Cancer Cell* **26**, 896-908 (2014).

- 773 22. Li, Y. et al. AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79  
774 methylation. *Cell* **159**, 558-71 (2014).
- 775 23. Wan, L. et al. ENL links histone acetylation to oncogenic gene expression in acute  
776 myeloid leukaemia. *Nature* **543**, 265-269 (2017).
- 777 24. Kim, S.K. et al. Human histone H3K79 methyltransferase DOT1L protein [corrected]  
778 binds actively transcribing RNA polymerase II to regulate gene expression. *J Biol*  
779 *Chem* **287**, 39698-709 (2012).
- 780 25. Worden, E.J. & Wolberger, C. Activation and regulation of H2B-Ubiquitin-dependent  
781 histone methyltransferases. *Curr Opin Struct Biol* **59**, 98-106 (2019).
- 782 26. van Welsem, T. et al. Dot1 promotes H2B ubiquitination by a methyltransferase-  
783 independent mechanism. *Nucleic Acids Res* **46**, 11251-11261 (2018).
- 784 27. Cecere, G., Hoersch, S., Jensen, M.B., Dixit, S. & Grishok, A. The ZFP-1(AF10)/DOT-1  
785 complex opposes H2B ubiquitination to reduce Pol II transcription. *Mol Cell* **50**, 894-  
786 907 (2013).
- 787 28. Feng, Y. et al. Early mammalian erythropoiesis requires the Dot1L  
788 methyltransferase. *Blood* **116**, 4483-91 (2010).
- 789 29. Cao, K. et al. DOT1L-controlled cell-fate determination and transcription elongation  
790 are independent of H3K79 methylation. *Proc Natl Acad Sci U S A* (2020).
- 791 30. Rahl, P.B. et al. c-Myc regulates transcriptional pause release. *Cell* **141**, 432-45  
792 (2010).
- 793 31. Fuchs, G. et al. 4sUDRB-seq: measuring genomewide transcriptional elongation rates  
794 and initiation frequencies within cells. *Genome Biol* **15**, R69 (2014).
- 795 32. Unnisa, Z. et al. Meis1 preserves hematopoietic stem cells in mice by limiting  
796 oxidative stress. *Blood* **120**, 4973-81 (2012).
- 797 33. Lawrence, H.J. et al. Loss of expression of the Hoxa-9 homeobox gene impairs the  
798 proliferation and repopulating ability of hematopoietic stem cells. *Blood* **106**, 3988-  
799 94 (2005).
- 800 34. Kaya-Okur, H.S. et al. CUT&Tag for efficient epigenomic profiling of small samples  
801 and single cells. *Nat Commun* **10**, 1930 (2019).
- 802 35. Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor.  
803 *Bioinformatics* **34**, i884-i890 (2018).
- 804 36. Langmead, B. & Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. *Nat*  
805 *Methods* **9**, 357-9 (2012).
- 806 37. Li, H. et al. The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**,  
807 2078-9 (2009).
- 808 38. Institute, B. Picard Toolkit. in *Broad Institute, GitHub repository* (2019).
- 809 39. Ramirez, F. et al. deepTools2: a next generation web server for deep-sequencing  
810 data analysis. *Nucleic Acids Res* **44**, W160-5 (2016).
- 811 40. Zhong, S. et al. High-throughput illumina strand-specific RNA sequencing library  
812 preparation. *Cold Spring Harb Protoc* **2011**, 940-9 (2011).
- 813 41. Kim, D., Paggi, J.M., Park, C., Bennett, C. & Salzberg, S.L. Graph-based genome  
814 alignment and genotyping with HISAT2 and HISAT-genotype. *Nat Biotechnol* **37**,  
815 907-915 (2019).
- 816 42. Liao, Y., Smyth, G.K. & Shi, W. featureCounts: an efficient general purpose program  
817 for assigning sequence reads to genomic features. *Bioinformatics* **30**, 923-30 (2014).

- 818 43. Love, M.I., Huber, W. & Anders, S. Moderated estimation of fold change and  
819 dispersion for RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014).
- 820 44. Yu, M. et al. RNA polymerase II-associated factor 1 regulates the release and  
821 phosphorylation of paused RNA polymerase II. *Science* **350**, 1383-1386 (2015).
- 822 45. Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). *Genome Biol* **9**, R137  
823 (2008).
- 824 46. McCarthy, D.J., Chen, Y. & Smyth, G.K. Differential expression analysis of multifactor  
825 RNA-Seq experiments with respect to biological variation. *Nucleic Acids Res* **40**,  
826 4288-97 (2012).
- 827 47. Kwak, H., Fuda, N.J., Core, L.J. & Lis, J.T. Precise maps of RNA polymerase reveal how  
828 promoters direct initiation and pausing. *Science* **339**, 950-3 (2013).
- 829 48. Chae, M., Danko, C.G. & Kraus, W.L. groHMM: a computational tool for identifying  
830 unannotated and cell type-specific transcription units from global run-on  
831 sequencing data. *BMC Bioinformatics* **16**, 222 (2015).
- 832 49. Morlan, J.D., Qu, K. & Sinicropi, D.V. Selective depletion of rRNA enables whole  
833 transcriptome profiling of archival fixed tissue. *PLoS One* **7**, e42882 (2012).
- 834 50. Danko, C.G. et al. Signaling pathways differentially affect RNA polymerase II  
835 initiation, pausing, and elongation rate in cells. *Mol Cell* **50**, 212-22 (2013).
- 836 51. Picelli, S. et al. Tn5 transposase and tagmentation procedures for massively scaled  
837 sequencing projects. *Genome Res* **24**, 2033-40 (2014).
- 838 52. Corces, M.R. et al. An improved ATAC-seq protocol reduces background and enables  
839 interrogation of frozen tissues. *Nat Methods* **14**, 959-962 (2017).
- 840 53. Lawrence, M. et al. Software for computing and annotating genomic ranges. *PLoS*  
841 *Comput Biol* **9**, e1003118 (2013).
- 842 54. Lawrence, M., Gentleman, R. & Carey, V. rtracklayer: an R package for interfacing  
843 with genome browsers. *Bioinformatics* **25**, 1841-2 (2009).
- 844 55. Yu, G., Wang, L.G. & He, Q.Y. CHIPseeker: an R/Bioconductor package for ChIP peak  
845 annotation, comparison and visualization. *Bioinformatics* **31**, 2382-3 (2015).
- 846 56. Yu, M. et al. Insights into GATA-1-mediated gene activation versus repression via  
847 genome-wide chromatin occupancy analysis. *Mol Cell* **36**, 682-95 (2009).
- 848